Champions Oncology

Champions Oncology reported adjusted earnings of $0.05 per share for Q1 2027 versus an expected -$0.01 and revenue of $15.2 million (forecast $15.05 million). Gross margin rose to 50% and adjusted EBITDA was about $700,000, while GAAP net loss narrowed to $426,000. Cash stood at $4.4 million with a cash outflow of roughly $500,000; management provided no detailed quarterly guidance and reiterated its focus on cost discipline and data licensing. Despite the results, the stock fell after hours as investors weighed the small market capitalization, cash burn and cautious outlook. » More on de.investing.com

Champions Oncology will present eight poster presentations at the 2026 AACR annual meeting in San Diego, showcasing research on KRAS‑mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, antibody‑drug conjugates and CAR‑T therapies. The studies use patient‑derived models combined with molecular, functional and phenotypic data to identify biomarkers, therapy responses and resistance mechanisms. The company highlights collaboration talks during the conference; the stock is trading near its 52‑week low, with analyst targets up to $12. » More on de.investing.com

Champions Oncology reported Q2 2025 revenue of USD 15m (+11% yoy) and an improved gross margin of 52% (prior year 45%). Operating income was USD 185,000, adjusted EBITDA about USD 800,000; cash balance USD 8.5m with no debt. The stock rose about 16% in after-hours trading following the release. The company is investing in its data platform, reviewing external financing options for subsidiary Corelia, and again aims for full-year revenue growth and a positive adjusted EBITDA. » More on de.investing.com